Positions
- Professor
-
Pediatrics-Hem-Onc Cell & Gene
Baylor College of Medicine
Houston, TX US
- Member
-
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States
Addresses
- TX Childs Feigin Ctr (Office)
-
Room: TXFC-176012
Houston, TX 77030
United States
- Texas Children's Hospital, Clinical Care Center (Clinic)
-
6701 Fannin St
14th floor
Houston, TX 77030
United States
Phone: (832) 822-4242
Professional Interests
- Bone Marrow Transplantation
- Cell and Gene Therapy
Professional Statement
Dr. Ahmed is a physician scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve therapy for brain tumors. Dr Ahmed's initial studies demonstrated that antigen-specific cytotoxic T cells could eradicate established brain tumors in medulloblastoma and Glioblastoma models. Subsequent studies have demonstrated that the tumor-specific T cells, unlike conventional therapies, can effectively target the stem cell compartment in the tumor eradicating experimental tumors in animal models. Aligning with his primary interest is studying the role of T cells in creating a tumor niche and studying T cell migration to distant tumor sites in the brain. Dr. Ahmed therefore has experience in developing and translating cell and gene therapy studies to the clinic. Currently, Dr. Ahmed is the principal investigator on 3 clinical trials targeting Glioblastoma and Osteosarcoma by administering tumor-specific T cells to. All studies are FDA, IRB, RAC and IBC approved.Websites
Selected Publications
- Fu X, Tao L, Rivera A, Williamson S, Song XT, Ahmed N, Zhang X "A simple and sensitive method for measuring tumor-specific T cell cytotoxicity.." PLoS ONE. 2010;5(7):e11867. Pubmed PMID: 20686618
- Ahmed N, Chizhevsky V "Acute hepatic sequestration associated with pneumococcal infection in a 5-year-old Boy with sickle beta degrees -thalassemia: a case report and review of the literature.." J. Pediatr. Hematol. Oncol.. 2007 Oct;29(10):720-4. Pubmed PMID: 17921856
- Salsman VS, Chow KK, Shaffer DR, Kadikoy H, Li XN, Gerken C, Perlaky L, Metelitsa LS, Gao X, Bhattacharjee M, Hirschi K, Heslop HE, Gottschalk S, Ahmed N "Crosstalk between Medulloblastoma Cells and Endothelium Triggers a Strong Chemotactic Signal Recruiting T Lymphocytes to the Tumor Microenvironment.." PLoS ONE. 2011;6(5):e20267. Pubmed PMID: 21647415
- Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, Leen AM, Bollard CM, Rooney CM, Heslop HE, Gottschalk S, Ahmed N "Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma.." J. Immunother.. 2012 Feb;35(2):159-68. Pubmed PMID: 22306904
- Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S "HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.." Clin. Cancer Res.. 2010 Jan 15;16(2):474-85. Pubmed PMID: 20068073
- Ahmed N, Gottschalk S "How to design effective vaccines: lessons from an old success story.." Expert Rev Vaccines. 2009 May;8(5):543-6. Pubmed PMID: 19397411
- Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S "Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.." Mol. Ther.. 2009 Oct;17(10):1779-87. Pubmed PMID: 19532139
- Rainusso N, Brawley VS, Ghazi A, Hicks MJ, Gottschalk S, Rosen JM, Ahmed N "Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.." Cancer Gene Ther.. 2012 Mar;19(3):212-7. Pubmed PMID: 22173710
- Byrd T, Grossman RG, Ahmed N "Medulloblastoma-biology and microenvironment: a review.." Pediatr Hematol Oncol. 2012 Sep;29(6):495-506. Pubmed PMID: 22742590
- Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM "PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor.." Mol. Ther.. 2011 Dec;19(12):2133-43. Pubmed PMID: 21772253
- Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S "Regression of experimental medulloblastoma following transfer of HER2-specific T cells.." Cancer Res.. 2007 Jun 15;67(12):5957-64. Pubmed PMID: 17575166
- Ahmed N, Leung KS, Rosenblatt H, Bollard CM, Gottschalk S, Myers GD, Carrum G, Heslop HE, Brenner MK, Krance RA "Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.." Biol. Blood Marrow Transplant.. 2008 Nov;14(11):1298-304. Pubmed PMID: 18940685
- Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso N, Wu MF, Liu H, Kew Y, Grossman RG, Powell S, Lee D, Ahmed N, Gottschalk S "T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma.." Mol. Ther.. 2013 Mar;21(3):629-37. Pubmed PMID: 23070117
- Ahmed N, Heslop HE, Mackall CL "T-cell-based therapies for malignancy and infection in childhood.." Pediatr. Clin. North Am.. 2010 Feb;57(1):83-96. Pubmed PMID: 20307713
- Ahmed N, Heslop HE "Viral lymphomagenesis.." Curr. Opin. Hematol.. 2006 Jul;13(4):254-9. Pubmed PMID: 16755222
Log In to edit your profile